Compare, Analyse Divis Laboratories with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ACTAVIS (US) - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   ACTAVIS
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ACTAVIS
Dec-18
DIVIS LABORATORIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,63914,244-   
Low Rs1,1159,555-   
Sales per share (Unadj.) Rs186.33,493.9-  
Earnings per share (Unadj.) Rs51.0-1,125.4-  
Cash flow per share (Unadj.) Rs57.3368.2-  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.814,410.8-  
Shares outstanding (eoy) m265.47332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.43.4 217.0%   
Avg P/E ratio x27.0-10.6 -255.6%  
P/CF ratio (eoy) x24.032.3 74.3%  
Price / Book Value ratio x5.30.8 637.1%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,5923,957,626 9.2%   
No. of employees `00011.816.9 70.1%   
Total wages/salary Rs m5,4230-   
Avg. sales/employee Rs Th4,175.168,762.2 6.1%   
Avg. wages/employee Rs Th457.70-   
Avg. net profit/employee Rs Th1,141.8-22,148.3 -5.2%   
INCOME DATA
Net Sales Rs m49,4631,162,081 4.3%  
Other income Rs m1,55622,223 7.0%   
Total revenues Rs m51,0191,184,304 4.3%   
Gross profit Rs m18,71830,452 61.5%  
Depreciation Rs m1,689496,764 0.3%   
Interest Rs m3567,059 0.1%   
Profit before tax Rs m18,551-511,148 -3.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0130,363 0.0%   
Tax Rs m5,023-6,478 -77.5%   
Profit after tax Rs m13,527-374,307 -3.6%  
Gross profit margin %37.82.6 1,444.1%  
Effective tax rate %27.11.3 2,136.8%   
Net profit margin %27.3-32.2 -84.9%  
BALANCE SHEET DATA
Current assets Rs m46,501476,625 9.8%   
Current liabilities Rs m8,468421,638 2.0%   
Net working cap to sales %76.94.7 1,625.0%  
Current ratio x5.51.1 485.8%  
Inventory Days Days13120 667.9%  
Debtors Days Days8666 129.5%  
Net fixed assets Rs m25,797131,541 19.6%   
Share capital Rs m5310-   
"Free" reserves Rs m68,9620-   
Net worth Rs m69,4934,793,042 1.4%   
Long term debt Rs m01,687,804 0.0%   
Total assets Rs m80,3837,492,615 1.1%  
Interest coverage x531.0-6.6 -8,018.6%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.60.2 396.7%   
Return on assets %16.9-4.1 -411.5%  
Return on equity %19.5-7.8 -249.3%  
Return on capital %26.7-4.8 -552.5%  
Exports to sales %00-   
Imports to sales %24.60-   
Net fx Rs m28,8330-   
CASH FLOW
From Operations Rs m9,543415,168 2.3%  
From Investments Rs m-6,854228,081 -3.0%  
From Financial Activity Rs m-2,459-712,552 0.3%  
Net Cashflow Rs m230-68,958 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.61 Rs / USD

Compare DIVIS LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: ELDER PHARMA  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  SANOFI INDIA  



Today's Market

Sensex Ends 134 Points Lower; Finance and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure during closing hours today and ended marginally lower.

Related Views On News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More
-->

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

REVEALED: 5 Pandemic-Proof Smallcaps You Should Know About...
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DIVIS LABORATORIES SHARE PRICE


Sep 18, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

FEATURED VIDEOS

A Contrarian View on Whether You Should Load Up on Small Caps

Will Bluechips Lose Luster After 25-25-25 Directive for Multicap Funds?

Is the Stock Market Rally Fake and Disconnected From Reality?

Generate Huge Gains with this Hidden Pattern in SBI

More Featured Videos

MARKET STATS